Annatto-derived GG for Statin-associated Myopathy

Recruiting now · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Myopathy; Primary

In brief

To evaluate the effects of 3-months annatto-derived geranylgeraniol (GG) supplementation on statin-associated skeletal muscle health.

Key facts

Study ID

NCT05312424

Run by

Texas Tech University Health Sciences Center

People needed

95

Starts

2022-07-15

Expected to finish

2027-12-31

Last updated by the study team

2025-09-12

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age ≥40 of either sex
• Statin-treated patients with muscle pain alone or accompanied by other symptoms.
• Patients currently receiving a statin who developed new-onset myalgias in within 90 day of initiation or a dosage increase

You may not qualify if…

• Malignancy or significant neurological or psychiatric disturbances, including alcohol or drug abuse.
• Woman who is pregnant, breastfeeding, or of childbearing potential and not taking adequate contraceptive precautions.
• Had CoQ10 supplement one month before starting the study.
• Genetic musculoskeletal and neurologic disorder known to affect skeletal muscle metabolism
• Had steroid medication one month before starting the study.

Where it is running

• Texas Tech University Health Sciences Center — Lubbock, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.